TNFRSF11A and osteoporosis: Then, a series of sRANKL-RANK small-molecular inhibitors was discovered based on this site, confirming the inhibitor’s selectivity toward sRANKL and, validating the efficacy of anti-osteoporosis activity of the sRANKL without causing immunosuppression side effects in vivo and in vitro.